Although further clinical trials are still needed, the dramatically differences of FBXW7 deletion and PIK3CA amplification between the subtype2 and subtype3 in our ESCC cohort, suggested that mTOR inhibitors and PI3K inhibitors may also suit for certain groups of ESCC patient. Here, MTOR is linked to esophageal squamous cell carcinoma.